Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Resectable or Unresectable Desmoplastic Melanoma
NCT02775851Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2017
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in desmoplastic melanoma (DM), sponsored by National Cancer Institute. Started Feb 2017; status: active, not recruiting.
02
Drugs
03
Conditions
desmoplastic melanoma (DM)
Beyond the preview
Go deeper on NCT02775851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02775851.